Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | GPR6 | P46095 | 2/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | QSOX1 | O00391 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31504201 | 1.00 | MAPT (0.51) | MAPTPPARGGPR6PANK3ALDH1A1 | |
| SCHEMBL22495405 | 0.90 | MAPT (0.58) | MAPTGPR6ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL21771104 | 0.85 | RAB9A (0.62) | MAPTPANK3ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL31504260 | 0.84 | PANK3 (0.52) | MAPTPPARGGPR6PANK3ALDH1A1 | |
| SCHEMBL22495282 | 0.84 | PANK3 (0.52) | MAPTPPARGGPR6PANK3ALDH1A1 | |
| SCHEMBL31504183 | 0.83 | LMNA (0.54) | MAPTALDH1A1L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL22495244 | 0.83 | LMNA (0.54) | MAPTALDH1A1L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL22495190 | 0.82 | RAB9A (0.53) | MAPTPPARGPANK3ALDH1A1SMN1; SMN2 | |
| SCHEMBL22495214 | 0.79 | RAB9A (0.64) | MAPTPPARGPANK3ALDH1A1SMN1; SMN2 | |
| SCHEMBL30172115 | 0.79 | MAPT (0.54) | MAPTPPARGPANK3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | claimed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | claimed |
| EP-3728234-A1 | RADIOLABELED COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | claimed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | claimed |
| CN-111511732-A | Radiolabelled compounds | 豪夫迈·罗氏有限公司 | 2020-08-07 | — | — | CN | claimed |
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3728234-A1 | RADIOLABELED COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111511732-A | Radiolabelled compounds | 豪夫迈·罗氏有限公司 | 2020-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541132-B2 | Radiolabeled compounds | SNCA, APP, BACE1 | MAPT 16/4885PPARG 2897/4885GPR6 3162/4885 |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | SNCA, APP, BACE1 | MAPT 17/4885PPARG 3173/4885GPR6 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.